Previsioni

Il prezzo obiettivo medio degli analisti è +16,74€ (+1,45%). La mediana è +16,74€ (+1,45%).

Acquista	4
Mantieni	10
Vendi	0

Notizie Vai al feed delle notizie

Kenvue raises quarterly dividend by 1.2% to $0.21

Kenvue has increased the quarterly dividend by 1.2% to $0.21 per common share. The payment will be made on August 26, 2026, to shareholders of record on August 12, 2026. Kenvue operates in the consumer health sector and owns brands such as Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena and Tylenol. » Altro su de.investing.com
Federal appeals court reinstates Tylenol lawsuits against Kenvue — stock falls

A three-judge panel in New York vacated the dismissal of suits against Kenvue and sent the case back for further proceedings, saying the lower court apparently exceeded its discretion when excluding three expert witnesses. Plaintiffs accuse Kenvue of concealing risks of a link between Tylenol use during pregnancy and autism; in 2023 about 500 suits had already been partly dismissed. Resuming the cases could lead to thousands more filings; a potential settlement could cost billions, Bloomberg Intelligence says. Kenvue shares fell about 1% on Monday. » Altro su de.investing.com
Kenvue: options trading picks up, calls dominate volume

Options volume on Kenvue rose sharply to 14,072 contracts, of which 12,948 were calls. Notably, the $20 call expiring July 17, 2026 accounted for 11,206 contracts. A put spread for August and several call spreads between August 2026 and February 2027 also saw activity. The stock traded at $19.55 (+1.93%), and three-month volatility fell to 22.51%. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2026, Kenvue ha già distribuito 0,54€ di dividendi. L'ultimo pagamento è avvenuto a agosto.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Kenvue ha registrato ricavi pari a 3,47Mld€ e un utile netto di 400,49M€

(EUR)	giu 2026	YoY
Ricavi	+3,47Mld	6,10%
Utile lordo	+2,02Mld	4,81%
Utile netto	+400,49M	11,82%
EBITDA	+731,59M	2,50%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+31,69Mld€
Numero di azioni	1,92Mld
Massimo/minimo a 52 settimane	+17,99€ - +12,04€
Rendimento da dividendo	+4,30%
Dividendi TTM	+0,71€
Beta	0,43
Rapporto P/E	+22,09
Rapporto PEG	+1,26
Rapporto P/B	+3,50
Rapporto P/S	+2,40

Profilo aziendale

Kenvue Inc. ist ein weltweit tätiges Unternehmen im Bereich der Verbrauchergesundheit. Das Unternehmen ist in drei Segmenten tätig: Self Care, Skin Health and Beauty und Essential Health. Das Segment Self Care bietet unter den Marken Tylenol, Nicorette und Zyrtec Produkte zur Behandlung von Husten, Erkältungen und Allergien, zur Schmerzbehandlung, für die Verdauung, zur Raucherentwöhnung und andere Produkte an. Das Segment Skin Health and Beauty bietet unter den Markennamen Neutrogena, Aveeno und OGX Gesichts- und Körperpflege, Haarpflege sowie Sonnen- und andere Pflegeprodukte an. Das Segment Essential Health bietet unter den Marken Listerine, Johnson's, Band-Aid und Stayfree Produkte für die Mund- und Babypflege, die Gesundheit von Frauen und die Wundpflege an. Das Unternehmen wurde im Jahr 2022 gegründet und hat seinen Hauptsitz in Skillman, New Jersey. Kenvue Inc. arbeitet als Tochtergesellschaft von Johnson & Johnson.

Nome	Kenvue
CEO	Kirk L. Perry
Sede centrale	Summit, nj Stati Uniti
Sito web	kenvue.com
Settore	Beni di prima necessità
Industria	Distribuzione e vendita di beni di prima necessità
Quotazione in borsa	04/05/2023
Dipendenti	21.890